Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging technologies for measuring different facets of immunity, and novel candidate biomarkers, the SITC Immune Biomarkers Oversight Committee has reconvened to review state of the art technologies, identify current hurdles to further success and to make recommendations to the field.The committee provides expert guidance and insights on the state of the art regarding biomarker identification and application in cancer immunotherapy to more rapidly move the field forward. Central points of focus include biomarker standardization, validation, and identification, as well as data and specimen sharing, collaboration across disciplines, and emergent technologies for investigation of novel candidate biomarkers from early phase trials.
In the video above, published by OncLive, SITC Immediate Past President Lisa H. Butterfield, PhD, discusses the SITC Immune Biomarkers Committee.
The SITC Immune Biomarkers Oversight Committee reconvened for a two-day workshop on critical next steps in the field, including:
A review of this meeting was published in the Journal for ImmunoTherapy of Cancer (JITC) on Dec. 4, 2018. Enduring materials from this program are available to the general public. Click here to access the presentations. Presentations and video recordings are available based on permission from presenters.
NCI/CCR and SITC co-sponsored a 2016 biomarkers meeting to review the state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward.The main goals were to provide updated information to a wide audience and solicit stakeholder participation in promoting successful immune biomarker research.
A review of this meeting was published in the Journal for ImmunoTherapy of Cancer (JITC) in March 2017.
MANUSCRIPT IN DEVELOPMENTClinical and Biomarker Data SharingMANUSCRIPT IN DEVELOPMENTResources and Useful ToolsValidation of Biomarkers to Predict Response to Immunotherapy in Cancer (two-part white paper) Journal for ImmunoTherapy of Cancer, November 2016
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy Journal for ImmunoTherapy of Cancer, May 2017
Systematic evaluation of immune regulation and modulation Journal for ImmunoTherapy of Cancer, March 2017
Novel technologies and emerging biomarkers for personalized cancer immunotherapy Journal for ImmunoTherapy of Cancer, January 2016
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery Journal of Translational Medicine, September 2011
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers Clinical Cancer Research, May 2011
Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force Journal of Translational Medicine, December 2010
A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" Journal of Translational Medicine, December 2008
Workshop on Cancer Biometrics: Identifying Biomarkers and Surrogates of Cancer in Patients Journal of Immunotherapy, March/April 2005
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy Journal of Immunotherapy, March/April 2002
Immune Monitoring Technology Primer Series
CHAIRSAlessandra Cesano, MD, PhDESSA Pharma Inc.
Sergio Rutella, MD, PhD, FRCPathThe John van Geest Cancer Research Centre
CHAIRSJennifer A. Wargo, MD, MMScThe University of Texas MD Anderson Cancer Center
Laurence Zitvogel, MD, PhDInstitut Gustave Roussy
CHAIRSSiwen Hu-Lieskovan, MD, PhD University of Utah
Holden T. Maecker, PhDStanford University
CHAIRSPriti S. Hegde, PhD Foundation Medicine
Jianda Yuan, MD, PhDMerck Research Laboratories
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org